Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation - KTVN Channel 2 - Reno Tahoe News Weather, Video -

Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation

  • Wendy Damonte's Health Watch ReportsMore>>

  • Request Remind Me 2 Kit

    Request a Remind Me 2 Kit

         More >>
  • REMSA Program Helps Reduce Hospital Visits

    REMSA Program Helps Reduce Hospital Visits

    Tuesday, September 16 2014 7:38 PM EDT2014-09-16 23:38:26 GMT
    One trip to the emergency room can set you back thousands of dollars - and many uninsured often turn to the emergency room for their primary care. REMSA launched a new program a couple of years ago designed to cut down on unnecessary hospital visits.More >>
    One trip to the emergency room can set you back thousands of dollars - and many uninsured often turn to the emergency room for their primary care. REMSA launched a new program a couple of years ago designed to cut down on unnecessary hospital visits.More >>
  • President Obama: Ebola Outbreak 'Spiraling Out of Control'

    President Obama: Ebola Outbreak 'Spiraling Out of Control'

    Tuesday, September 16 2014 6:55 PM EDT2014-09-16 22:55:15 GMT
    President Obama visited the Centers for Disease Control and Prevention on Tuesday to discuss the growing Ebola crisis across the world. He said the U.S. needs to address the deadly outbreak.More >>
    President Obama visited the Centers for Disease Control and Prevention on Tuesday to discuss the growing Ebola crisis across the world. He said the U.S. needs to address the deadly outbreak.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Miltenyi Biotec

BERGISCH GLADBACH, Germany, August 14, 2014 /PRNewswire/ --

Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio.    

Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec's portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.

"It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale," said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. "With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner."

Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.

About Miltenyi Biotec 

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company's integrated tools support research at every level, from basic research to translational research to clinical application. Their technologies cover techniques of sample preparation, cell isolation, flow sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The company's more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Trusted around the world, the Miltenyi Biotec brand continues to set new standards in the industry. Miltenyi Biotec has more than 1,400 employees in 25 countries.

Media Contact:
Claire England
Tel: +44-(0)1480-471045
claire.england@phoenixmarcom.co.uk

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Sarkes Tarzian, Inc. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.